CTLA4 and myositis disease: Regarding the type of ICI used, patients treated with anti-PD(L)1 alone were more in proportion to have myositis (35/103, 34%, versus 8/43, 18.6%; P = 0.007) or limbic encephalitis (15/103, 14.6%; versus 1/43, 2.3%; P = 0.04), while patients treated with anti-CTLA4 (alone or combined with anti-PD(L)1) were more in proportion to have polyradiculoneuropathy (14/43, 32.6% versus 9/103, 8.7%; P < 0.001) or meningitis (6/43, 14%; versus 2/101, 2%; P = 0.008; Fig. 2).